StockData
Amgen Inc logo

Amgen Inc (AMGN) stock

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3023% above fair value
$435.64−3.18 (-0.72%)

Close on Nov 20, 2026Market cap $235.52BP/E 25.3Yield 2.22%

Amgen free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Amgen's free cash flow for the twelve months ending Sep 30, 2026 was $9.58B, down 17.0% year over year. For fiscal 2025 it was $8.10B, down 22.1% from the year before. Over ten years it grew -1.2% a year on average. The highest annual figure on record is $10.56B in fiscal 2018.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$8.10B-22.1%
FY2024Dec 31, 2024$10.39B+41.2%
FY2023Dec 31, 2023$7.36B-16.2%
FY2022Dec 31, 2022$8.79B+4.8%
FY2021Dec 31, 2021$8.38B-15.2%
FY2020Dec 31, 2020$9.89B+15.9%
FY2019Dec 31, 2019$8.53B-19.2%
FY2018Dec 31, 2018$10.56B+0.4%
FY2017Dec 31, 2017$10.51B+9.3%
FY2016Dec 31, 2016$9.62B+5.2%
FY2015Dec 31, 2015$9.14B+11.0%
FY2014Dec 31, 2014$8.23B+47.1%
FY2013Dec 31, 2013$5.60B+7.8%
FY2012Dec 31, 2012$5.19B+14.1%
FY2011Dec 31, 2011$4.55B-12.6%
FY2010Dec 31, 2010$5.21B-10.3%
FY2009Dec 31, 2009$5.81B+9.2%
FY2008Dec 31, 2008$5.32B+28.6%
FY2007Dec 31, 2007$4.13B–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$3.65B-14.0%
Q2 FY2026Jun 30, 2026$3.49B+82.6%
Q1 FY2026Mar 31, 2026$1.48B+50.7%
Q4 FY2025Dec 31, 2025$961.00M-78.2%
Q3 FY2025Sep 30, 2025$4.25B+28.2%
Q2 FY2025Jun 30, 2025$1.91B-14.0%
Q1 FY2025Mar 31, 2025$980.00M+113.5%
Q4 FY2024Dec 31, 2024$4.40B+1422.5%
Q3 FY2024Sep 30, 2024$3.31B+31.9%
Q2 FY2024Jun 30, 2024$2.22B-42.1%
Q1 FY2024Mar 31, 2024$459.00M-36.3%
Q4 FY2023Dec 31, 2023$289.00M-87.5%
Q3 FY2023Sep 30, 2023$2.51B-10.9%
Q2 FY2023Jun 30, 2023$3.84B+127.9%
Q1 FY2023Mar 31, 2023$720.00M-63.5%
Q4 FY2022Dec 31, 2022$2.31B-8.4%
Q3 FY2022Sep 30, 2022$2.82B+45.4%
Q2 FY2022Jun 30, 2022$1.68B-14.9%
Q1 FY2022Mar 31, 2022$1.97B-38.9%
Q4 FY2021Dec 31, 2021$2.52B-6.1%
Q1 FY2021Mar 31, 2021$1.94B-2.7%
Q4 FY2020Dec 31, 2020$1.98B+55.9%
Q3 FY2020Sep 30, 2020$3.23B+87.0%
Q2 FY2020Jun 30, 2020$2.68B-9.6%
Q1 FY2020Mar 31, 2020$1.99B-35.8%
Q2 FY2019Jun 30, 2019$1.27B-33.7%
Q1 FY2019Mar 31, 2019$1.73B-32.8%
Q4 FY2018Dec 31, 2018$2.97B+3.8%
Q3 FY2018Sep 30, 2018$3.10B-5.9%
Q2 FY2018Jun 30, 2018$1.92B-10.6%
Q1 FY2018Mar 31, 2018$2.57B+16.0%
Q4 FY2017Dec 31, 2017$2.86B-0.5%
Q3 FY2017Sep 30, 2017$3.30B+32.1%
Q2 FY2017Jun 30, 2017$2.14B-14.0%
Q1 FY2017Mar 31, 2017$2.22B–
Q4 FY2016Dec 31, 2016$2.87B–
Q3 FY2016Sep 30, 2016$2.50B–
Q2 FY2016Jun 30, 2016$2.49B–

More Amgen figures

See a number that looks wrong?